Vaxine Pty Ltd

Institut National De La Sante Et De La Recherche Medicale

Universitéde Strasbourg

Johns Hopkins University

Unm Rainforest Innovations

University of Pittsburgh

Calder Biosciences Inc.

Nikolai Petrovsky

Vincent Marion

Bryce Chackerian

David S Peabody

Fidel P Zavala

Christopher P Marshall

Peter D Cooper

Lucia Jelinkova

Lucie Jelinkova

Kerry McGarr Empey

An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NPDPNANPNVDPNAN (amino acids 5-19 of SEQ ID NO:1) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria.

Malaria immunogen and methods for using same

An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NANPNVDPNANPNVD (SEQ ID NO:2) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. Alternatively, the immunogen may be administered to an individual having or at risk of havingblood stage parasitemia. In some cases, the immunogen can be administered in combination with another therapeutic agent for treating malaria ofblood stage parasitemia.

The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by &#x3b1;PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of &#x3b1;PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of &#x3b1;PKC on ALMS1.

Target for diabetes treatment and prevention

Disclosed herein are compositions for vaccination against respiratory syncytial virus (RSV) comprising a RSV F polypeptide stabilized in a prefusion conformation and an inulin adjuvant. Also disclosed herein are methods of vaccinating a subject against a respiratory syncytial virus (RSV) infection comprising administering to the subject an RSV F polypeptide stabilized in a prefusion conformation and an inulin adjuvant. In some embodiments, the subject is a female, and the method can reduce RSV infection in the subject and/or in the offspring of the subject. In some embodiments, the method decreases vaccine-enhanced respiratory disease (VERD) and/or eosinophilia in the subject or offspring of the subject.

Compositions and methods for vaccination against respiratory syncytial virus infection

The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

Peptides for treatment and prevention of hyperglycaemia

The present invention provides a pharmaceutically acceptable composition comprising: particles of inulin; a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), and an antigen for use inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.

Vaccine adjuvant composition comprising inulin particles

The present invention relates to a new polymorphic form of inulin, designated delta inulin (dIN), to methods for the preparation of dIN, compositions comprising dIN and uses thereof. The present invention also relates to the use of dIN and compositions comprising dIN in the preparation of gamma inulin (gIN), compositions comprising gIN and uses thereof.

Growing community of inventors

Adelaide, Australia

Nikolai Petrovsky